IL10 and arthritic joint disease: In this experimental paradigm, PDRN significantly improved the clinical signs of arthritis, reduced the histological damage and blunted the cartilage content and blood levels of several inflammatory cytokine, while increased the expression of the anti-inflammatory cytokine Interleukin-10 (IL-10).